Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report report published on Monday,Benzinga reports. The firm currently has a $100.00 price objective on the stock.

MNPR has been the topic of several other research reports. BTIG Research reiterated a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a report on Monday, February 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Morgan Stanley began coverage on shares of Monopar Therapeutics in a report on Friday, January 9th. They set an “overweight” rating and a $115.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $107.00.

Monopar Therapeutics Trading Down 1.5%

Shares of MNPR stock opened at $53.29 on Monday. The firm’s fifty day moving average price is $59.29 and its two-hundred day moving average price is $70.99. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00. The firm has a market capitalization of $355.98 million, a P/E ratio of -29.28 and a beta of 1.58.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10). As a group, equities research analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new position in shares of Monopar Therapeutics in the third quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Monopar Therapeutics during the 2nd quarter worth about $34,000. BNP Paribas Financial Markets boosted its holdings in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics in the 4th quarter valued at about $65,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.